Department of Radiation Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
Ann Transl Med. 2015 Dec;3(21):325. doi: 10.3978/j.issn.2305-5839.2015.12.21.
Patients with multiple brain metastases are often treated with whole brain radiation therapy (WBRT). Second course of WBRT is an important treatment option for patients with clinical or radiological intracranial disease progression. This study examines the outcomes in patients with multiple brain metastases who underwent reirradiation.
We examined the medical records of 34 patients with multiple brain metastases who were treated WBRT. The median dose for the first course of WBRT was 30 Gy (range, 25-30 Gy) and for the second course 25 Gy (range, 20-30 Gy). Statistical analyses were performed with using Cox regression analyses, log-rank test and Kaplan-Meier method.
The median Karnofsky performance status (KPS) was 80 (range, 50-100) before reirradiation. Patients with KPS of >70 had a median survival of 11.4 months, compared to 2.2 months with KPS of ≤70 (P=0.012) and patients who have severe symptoms at the time of reirradiation with median survival 2.2 months while those with mild symptoms had a median of 4.8 months survival (P=0.08). The median overall survival for all patients after diagnosis of metastases was 24.7 months, after the re-irradiation WBRT (re-WBRT) it was 5.3 months (95% CI, 4.08-6.62) and from the diagnosis of primary tumor was 27.1 months (95% CI, 17.75-37.04).
In select patients who have good performance status and who do not have severe symptoms might benefit from re-WBRT and re-WBRT seems to be associated with minimal toxicity in patients treated with lower palliation doses.
患有多发脑转移的患者通常接受全脑放疗(WBRT)。对于有临床或影像学颅内疾病进展的患者,第二程 WBRT 是一种重要的治疗选择。本研究评估了接受再放疗的多发脑转移患者的结局。
我们检查了 34 名接受 WBRT 治疗的多发脑转移患者的病历。第一程 WBRT 的中位剂量为 30 Gy(范围,25-30 Gy),第二程为 25 Gy(范围,20-30 Gy)。使用 Cox 回归分析、对数秩检验和 Kaplan-Meier 方法进行统计分析。
再放疗前的中位 Karnofsky 表现状态(KPS)为 80(范围,50-100)。KPS>70 的患者中位生存期为 11.4 个月,而 KPS≤70 的患者中位生存期为 2.2 个月(P=0.012);再放疗时症状严重的患者中位生存期为 2.2 个月,而症状轻微的患者中位生存期为 4.8 个月(P=0.08)。所有患者从转移诊断开始的中位总生存期为 24.7 个月,再放疗 WBRT(再-WBRT)后为 5.3 个月(95%CI,4.08-6.62),从原发肿瘤诊断开始为 27.1 个月(95%CI,17.75-37.04)。
在表现状态良好且无严重症状的选择患者中,再-WBRT 可能获益,并且在接受低姑息剂量治疗的患者中,再-WBRT 似乎与最小的毒性相关。